The estimated Net Worth of William R Ringo is at least $910 Thousand dollars as of 11 November 2020. Mr. Ringo owns over 78,959 units of Assembly Biosciences Inc stock worth over $625,680 and over the last 21 years he sold ASMB stock worth over $76,142. In addition, he makes $208,457 as Non-Executive Independent Chairman of the Board at Assembly Biosciences Inc.
William has made over 52 trades of the Assembly Biosciences Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 78,959 units of ASMB stock worth $190,291 on 11 November 2020.
The largest trade he's ever made was exercising 78,959 units of Assembly Biosciences Inc stock on 11 November 2020 worth over $190,291. On average, William trades about 1,811 units every 23 days since 2003. As of 11 November 2020 he still owns at least 36,000 units of Assembly Biosciences Inc stock.
You can see the complete history of Mr. Ringo stock trades at the bottom of the page.
William R. Ringo Jr. serves as Non-Executive Independent Chairman of the Board of the Company. Mr. Ringo became a director upon the closing of the Merger in July 2014 and became non-executive Chairman of the Board in February 2015. Mr. Ringo has served as Interim Chief Executive Officer of Five Prime Therapeutics, Inc. (Five Prime) since September 2019. From July 2010 until December 2015, Mr. Ringo was a senior advisor with Barclays Capital, the global investment banking division of Barclays Bank PLC. From July 2010 until December 2015, Mr. Ringo served as a strategic advisor with Sofinnova Ventures, a life sciences-focused investment firm. Prior to his advisory roles with Barclays Capital and Sofinnova Ventures, Mr. Ringo served as Senior Vice President of Strategy and Business Development for Pfizer Inc., a biopharmaceutical company, from April 2008 until his retirement in April 2010. From 2004 to 2006, Mr. Ringo served as President and Chief Executive Officer of Abgenix, Inc., a biotechnology company acquired by Amgen, Inc. Mr. Ringo served on the Onyx Pharmaceuticals, Inc. board of directors from February 2011 until the October 2013 acquisition by Amgen, Inc. From 2001 to 2007, he served on various boards of directors, including the following public companies: Encysive Pharmaceuticals, Inc.; Inspire Pharmaceuticals, Inc.; and InterMune, Inc., where he was the non-executive chairman of the board of directors after serving as interim Chief Executive Officer from June 2003 to September 2003. From 1994 to 2002, he served as a director and chairman of the board for Community Health Systems, Inc. His experience in the global pharmaceutical sector also includes nearly 30 years with Lilly. Over the course of his career with Lilly, Mr. Ringo served in numerous executive roles, including Product Group President for oncology and critical care, President of internal medicine products, President of the infectious diseases business unit, and Vice President of sales and marketing for U.S. pharmaceuticals.
As the Non-Executive Independent Chairman of the Board of Assembly Biosciences Inc, the total compensation of William Ringo at Assembly Biosciences Inc is $208,457. There are 7 executives at Assembly Biosciences Inc getting paid more, with John McHutchison having the highest compensation of $7,007,210.
William Ringo is 74, he's been the Non-Executive Independent Chairman of the Board of Assembly Biosciences Inc since 2015. There are no older and 18 younger executives at Assembly Biosciences Inc.
William's mailing address filed with the SEC is C/O ASSEMBLY BIOSCIENCES, INC., TWO TOWER PLACE, 7TH FLOOR, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 10 years, insiders at Assembly Biosciences Inc have traded over $1,523,622 worth of Assembly Biosciences Inc stock and bought 1,245,980 units worth $1,060,065 . The most active insiders traders include Sciences, Inc. Gilead, Myron Z Holubiak, and Helen Susan Kim. On average, Assembly Biosciences Inc executives and independent directors trade stock every 46 days with the average trade being worth of $389,399. The most recent stock trade was executed by Nicole S White on 2 August 2024, trading 785 units of ASMB stock currently worth $11,171.
assembly biosciences, inc. (nasdaq: asmb) is a public clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and novel oral live biotherapeutics for disorders associated with the microbiome. assembly is developing two innovative platform programs: an hbv program advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and a microbiome program developing novel oral live biotherapeutics designed to address diseases associated with the microbiome. assembly’s hbv program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic hbv. the company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current good manufacturing practices and a patent-pending delivery system, gemicel®, which allows for targeted ora
Assembly Biosciences Inc executives and other stock owners filed with the SEC include: